PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 31, 2024New England Journal of Medicine157 citations

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

View Full Paper
AHAndreas HochhausJWJianxiang WangDKDong‐Wook Kim

Key Points

  • Asciminib specifically targets the ABL myristoyl pocket to inhibit BCR::ABL1, offering an alternative to frontline ATP-competitive inhibitors.
  • Evaluation of newly diagnosed chronic myeloid leukemia highlights the requirement for long-term frontline therapy with sustained tolerability.
  • Targeting the ABL myristoyl pocket with asciminib may offer better efficacy and reduced side effects over standard tyrosine kinase inhibitors.

Abstract

Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better efficacy and safety and fewer side effects than currently available frontline ATP-competitive tyrosine kinase inhibitors (TKIs).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hochhaus et al. (2024) studied this question.

synapsesocial.com/papers/68e67617b6db6435875fff38https://doi.org/10.1056/nejmoa2400858
Ask AI
Helpful
Bookmark
Share
View Full Paper